Previous 10 | Next 10 |
STAMFORD, Conn., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announ...
SWK Holdings' (SWKH) subsidiary, Enteris BioPharma, has received a milestone payment of $2.5M from Cara Therapeutics (CARA) related to the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA, the oral formulation of CR845/difelikefalin.SWK is ent...
SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics First of multiple anticipated milestone payments related to the development of Oral KORSUVA™ PR Newswire DALLAS, Oct. 27, 2020 DALLAS , Oct. 27, 2020 /PR...
- Results from global KALM-2 p ivotal Phase 3 t rial of KORSUVA ™ Injection in h emodialysis p atients with p ruritus to be presented – - NDA submission for KORSUVA Injection on track for fourth qu...
Aptinyx (APTX) +98% on reporting positive top-line data from Phase 2 study of NYX-783.Cleveland BioLabs (CBLI) +46% in reaction to its planned merger with biopharmaceutical outfit Cytocom.Recon Technology (RCON) +42%.ATIF Holdings (ATIF) +26% after entering into ...
Cara Therapeutics (CARA) jumps 12% in premarket on moderate volume, after announcing a profit-sharing deal with Vifor Pharma (GNHAF), for the commercialization of intravenous ((IV)) Korsuva as a treatment of chronic kidney disease-associated pruritus in the U.S. dialysis market...
Vifor Pharma secures commercial rights for IV Korsuva in non- Fresenius Medical Care dialysis clinics representing approx. 66% of the market , under a profit - sharing arrangement with Cara Cara will receive a...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Cara Therapeutics (CARA) appoints Thomas Reilly as CFO, effective October 1, 2020.He joins Cara from Allergan, now part of AbbVie, where he served as Finance Head for the U.S. General Medicine Commercial Business. Source: Press Release For further details see: New finance chief at Cara ...
STAMFORD, Conn., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announ...
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...